Simultaneous targeting of mitochondrial metabolism and immune checkpoints as a new strategy for renal cancer therapy

0556526 - BTÚ 2023 RIV GB eng J - Článek v odborném periodiku
Štemberková-Hubáčková, Soňa - Zobalová, Renata - Dubišová, Maria - Šmigová, J. - Dvořáková, Šárka - Kořínková, Klára - Ezrová, Zuzana - Endaya, Berwini - Blažková, Kristýna - Vlčák, Erik - Brisudová, Petra - Le, Dan-Diem Thi - Juhás, Štefan - Rosel, D. - Kelemen, Daniela Cristina - Sovilj, Dana - Vačurová, Eliška - Čajka, Tomáš - Filimonenko, Vlada - Dong, L. - Anděra, Ladislav - Hozák, Pavel - Brabek, J. - Bielcikova, Z. - Štursa, Jan - Werner, Lukáš - Neužil, Jiří
Simultaneous targeting of mitochondrial metabolism and immune checkpoints as a new strategy for renal cancer therapy.
Clinical and Translational Medicine. Roč. 12, č. 3 (2022), č. článku e645. ISSN 2001-1326. E-ISSN 2001-1326
Grant CEP: GA ČR(CZ) GA20-05942S; GA ČR(CZ) GX21-04607X; GA ČR(CZ) GA18-02550S; GA ČR(CZ) GA19-08772S; GA MZd NU21-03-00195; GA MŠMT(CZ) LM2018129; GA MŠMT(CZ) ED1.1.00/02.0109; GA MŠMT LTC19048; GA MŠMT(CZ) LO1609; GA MŠMT(CZ) EF16_013/0001775
Grant ostatní: AV ČR(CZ) StrategieAV21/18
Program: StrategieAV
Institucionální podpora: RVO:86652036 ; RVO:68378050 ; RVO:67985904 ; RVO:67985823
Klíčová slova: Mitochondrially targeted tamoxifen * Renal cancer * Immunotherapy
Obor OECD: Pathology
Impakt faktor: 10.6, rok: 2022
Způsob publikování: Open access
https://onlinelibrary.wiley.com/doi/10.1002/ctm2.645

Mitochondrially targeted tamoxifen (MitoTam) has recently undergone phase 1/1b clinical trial in patients with various solid tumors. Since patients with clear cell renal carcinoma showed the highest response of the tested diagnoses, we studied the effect of MitoTam on renal cancer in vitro and in vivo to reveal its mechanism of action in more detail and to better understand its benefit for patients. Using primarily the murine RenCa renal cancer cell line and the derived syngeneic mouse tumor model, we studied mechanism of MitoTam toxicity including the mode of death, the role of mitochondria in the effects of the agent, and its efficacy in suppressing syngeneic tumors in mice alone and in combination with the immune checkpoint inhibitors (ICIs), monoclonal antibodies blocking PD-1 and PD-L1. Our findings show a complex effect of MitoTam on mitochondrial function and integrity of renal cancer cells. The agent inhibits complex I-dependent respiration and lowers mitochondrial potential, which results in activation of necroptosis as the major mode of cell death. As a consequence, MitoTam reduces growth of renal tumors as well as metastatic spread of tumor cells via specific targeting of malignant tissue in a mouse model. Moreover, combination of MitoTam with immunotherapy to enhance its anti-cancer efficacy shows significantly increased suppression of tumor growth as well as increased survival of experimental animals compared to single agent treatment. Our data provide a mechanistic rationale for testing of both mono and/or combinatorial therapy with MitoTam plus ICIs in renal carcinomas in Phase 2 trial.
Trvalý link: http://hdl.handle.net/11104/0331774